These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36593103)

  • 21. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.
    Li Y; Zhou T; Cheng X; Li D; Zhao M; Zheng WV
    Bioengineered; 2022 Mar; 13(3):4730-4743. PubMed ID: 35184646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
    Guo S; Wang X; Zhou H; Gao Y; Wang P; Zhi H; Sun Y; Zhang Y; Gan J; Xiao Y; Ning S
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression.
    Barnwal A; Tamang R; Sanjeev Das ; Bhattacharyya J
    Br J Cancer; 2023 Oct; 129(6):1007-1021. PubMed ID: 37400678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
    Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
    Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis.
    Tan HY; Wang N; Zhang C; Chan YT; Yuen MF; Feng Y
    Hepatology; 2021 Jun; 73(6):2326-2341. PubMed ID: 33068461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.
    Schneider C; Teufel A; Yevsa T; Staib F; Hohmeyer A; Walenda G; Zimmermann HW; Vucur M; Huss S; Gassler N; Wasmuth HE; Lira SA; Zender L; Luedde T; Trautwein C; Tacke F
    Gut; 2012 Dec; 61(12):1733-43. PubMed ID: 22267597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
    Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
    Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circular RNA hsa_circ_0005239 contributes to hepatocellular carcinoma cell migration, invasion, and angiogenesis by targeting the miR-34a-5p/PD-L1 axis.
    He T; Huang J; Liang H; Zhong B; Xu G; Zhu X
    Cell Biol Int; 2023 Sep; 47(9):1519-1534. PubMed ID: 37208963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
    Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.
    Liu Y; Xu Q; Deng F; Zheng Z; Luo J; Wang P; Zhou J; Lu X; Zhang L; Chen Z; Zhang Q; Chen Q; Zuo D
    J Exp Clin Cancer Res; 2023 Feb; 42(1):38. PubMed ID: 36721234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages.
    Liu J; Fan L; Yu H; Zhang J; He Y; Feng D; Wang F; Li X; Liu Q; Li Y; Guo Z; Gao B; Wei W; Wang H; Sun G
    Hepatology; 2019 Jul; 70(1):241-258. PubMed ID: 30854665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
    Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
    Tan Z; Chiu MS; Yang X; Yue M; Cheung TT; Zhou D; Wang Y; Chan AW; Yan CW; Kwan KY; Wong YC; Li X; Zhou J; To KF; Zhu J; Lo CM; Cheng AS; Chan SL; Liu L; Song YQ; Man K; Chen Z
    Gut; 2023 Aug; 72(8):1568-1580. PubMed ID: 36450387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.
    Zhang X; Pan B; Qiu J; Ke X; Shen S; Wang X; Tang N
    Int J Exp Pathol; 2022 Jun; 103(3):102-111. PubMed ID: 35429078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SOX12 Facilitates Hepatocellular Carcinoma Progression and Metastasis through Promoting Regulatory T-Cells Infiltration and Immunosuppression.
    Luo X; Huang W; Li S; Sun M; Hu D; Jiang J; Zhang Z; Wang Y; Wang Y; Zhang J; Wu Z; Ji X; Liu D; Chen X; Zhang B; Liang H; Li Y; Liu B; Wang S; Xu X; Nie Y; Wu K; Fan D; Xia L
    Adv Sci (Weinh); 2024 Sep; 11(36):e2310304. PubMed ID: 39072947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p.
    Sun Y; Wang Q; Zhang Y; Geng M; Wei Y; Liu Y; Liu S; Petersen RB; Yue J; Huang K; Zheng L
    J Hepatol; 2020 Sep; 73(3):603-615. PubMed ID: 32593682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.